Michell Professor of Medicine
University of Adelaide

Printed as of 5/9/2025

Disclosures

Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)	
Self				
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease	
Terumo	Research/Research Grants ‡ PAMICO	Significant (>= \$5,000)	Acute Coronary Syndromes	

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Enity Name	Relationship Category Compensation Level		Topic Area(s)
Self			
The Hospital research Foundation Group	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
The University of Adelaide † National Health and Medical Research Council	Research/Research Grants ‡ PAMICO	Significant (>= \$5,000)	Acute Coronary Syndromes
University of Adelaide † Commercial Accelerator Scheme	Research/Research Grants ‡ The anti-anginal benefits of Zibotentan in the coronary Slow Flow Phenomenon.	Significant (>= \$5,000)	Stable Ischemic Heart Disease

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
PREVAIL	New Amsterdam	
VICTORION-2	Novartis Corporation	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/4/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/4/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/4/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/26/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members

involved in College governance, including disclosure statements. Compliance with	ding all committees and task forces, th this process is mandatory for part	programmatic, certified educationa icipation in College activities.	l, chapter, and other activities must p	provide complete, timely, accurate, and signed
alouiou o catoliiono. Compilano m	and proceed to managery for pair	ioipadon in conogo douvidos.		